July 6, 2021
Urovant Sciences Named One of the 2021 Best Places to Work in Orange County
June 29, 2021
Urovant Sciences and Sunovion Pharmaceuticals Launch Primary Care Co-Promotion of GEMTESA® (vibegron) for Patients with Overactive Bladder
April 15, 2021
Urovant Sciences Announces Publication of Positive Long-Term Clinical Safety and Efficacy Data on the FDA-Approved Overactive Bladder Therapy, GEMTESA® (vibegron), in the Journal of Urology
April 12, 2021
Urovant Sciences Announces U.S. Commercial Launch of GEMTESA® (vibegron) 75 mg Tablets for Patients with Overactive Bladder
February 12, 2021
Urovant Sciences Provides Merger Update and Reports Third Quarter Fiscal Year 2020 Results
February 11, 2021
Urovant Sciences Announces Progression of URO-902 Phase 2a Trial Following Positive Recommendation from the Data and Safety Monitoring Board